Core Insights - Novartis received FDA approval for a label expansion of its psoriasis drug Cosentyx, now indicated for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor available for this demographic [1][7] - Cosentyx generated sales of $6.7 billion in 2025, reflecting an 8% increase from 2024, driven by demand from recent launches and growth in core indications [5][7] - The approval for pediatric use is supported by adult HS studies and pharmacokinetic modeling, indicating comparable drug exposure between pediatric and adult patients [3][4] Product and Market Performance - Cosentyx is already approved for multiple conditions, including HS, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, marking its fourth pediatric indication [4][7] - The drug's sales growth is attributed to continued demand from recent launches, including the HS indication and an intravenous formulation in the U.S. [5][7] - However, Cosentyx is set to lose exclusivity in the U.S. in 2029, which may impact future sales [8] Strategic Developments - Novartis is focusing on key growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix to support overall revenue growth [10] - The company recently acquired Avidity Biosciences, enhancing its neuromuscular pipeline and potentially unlocking multi-billion-dollar market opportunities with product launches targeted before 2030 [11][12] - Novartis projects a net sales compound annual growth rate (CAGR) of 5-6% at constant currency from 2025 to 2030, bolstered by advancements in its late-stage pipeline [12]

Financial Performance - Royalty Pharma reported a 16% increase in total portfolio receipts for 2025 and an 18% increase in Q4 alone [1][2] - The company achieved a 15.8% return on invested capital and met its five-year capital deployment target of $10 billion to $12 billion a year ahead of schedule [1][2] Strategic Transactions - The company completed $4.7 billion in transactions focused on attractive therapies and received positive clinical and regulatory milestones, including FDA approval of Myqorzo [2] - Management emphasized the growing importance of synthetic royalties as an alternative to traditional debt or equity financing for biotech firms [2] Future Outlook - Despite current momentum, Royalty Pharma is preparing for headwinds in 2026, including the loss of exclusivity for Promacta and the introduction of a biosimilar for Tysabri in the US market [3] - The company expects portfolio receipts in 2026 to range between $3.275 billion and $3.425 billion, indicating a modest growth forecast of 3% to 8% [3]

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Insights - Novartis (NVS) announced positive results from the late-stage III ALIGN study for its kidney disease drug Vanrafia (atrasentan) [1][9] - The ALIGN study demonstrated that Vanrafia effectively slows the decline of kidney function in patients with IgA nephropathy [3][4] Study Results - Vanrafia showed a significant difference in estimated glomerular filtration rate (eGFR) change from baseline compared to placebo, with a 2.39 ml/min/1.73m² difference at week 136 and a 2.59 ml/min/1.73m² difference at week 132 [3][4] - The study included a subgroup of patients receiving SGLT2 inhibitors, who also exhibited similar benefits [4] Regulatory Status - Vanrafia received accelerated approval in the United States and China in 2025 for reducing proteinuria in adults with IgA nephropathy, with plans for traditional approval in 2026 [5][9] Product Portfolio - Novartis' renal portfolio includes Fabhalta (iptacopan), which is approved for treating adults with paroxysmal nocturnal hemoglobinuria and has also received accelerated approval for IgA nephropathy [6] - Fabhalta generated sales of $155 million in Q4 and $505 million in 2025 [7] Market Context - 2026 is a critical year for Novartis due to the patent expiry of its cardiovascular drug Entresto, which is the largest in its history [8] - Novartis shares have increased by 52.9% over the past year, outperforming the industry growth of 20.6% [8]

Core Insights - Royalty Pharma experienced a "landmark year" in 2025, achieving double-digit growth in both portfolio and royalty receipts, and internalizing its external manager to enhance governance and reduce costs [2][5][18] Financial Performance - The company reported a return on invested capital (ROIC) of 15.8% and return on equity (ROE) of 22.8% for 2025 [5] - Royalty receipts grew by 13% for the year and 17% in the fourth quarter, while portfolio receipts increased by 16% for the year and 18% in the fourth quarter [13] - The company ended 2025 with $619 million in cash, $9.2 billion in debt, and a leverage ratio of approximately 3x [3][15] Cost Management - Management expects to achieve $100 million in cost savings in 2026 due to the internalization of the external manager, aiming for an operating and professional cost ratio of 4%–5% over time [1][5] Strategic Transactions - In 2025, Royalty Pharma executed eight transactions with a total announced value of $4.7 billion, deploying $2.6 billion, marking its strongest year for synthetic royalties [4][6][7] - The company reviewed over 480 potential royalty transactions, resulting in 109 in-depth reviews and 35 proposals [6] 2026 Guidance - For 2026, management guided portfolio receipts of $3.275 billion to $3.425 billion, implying a royalty growth of approximately 3% to 8% [3][16] - The guidance reflects anticipated headwinds from product loss of exclusivity and the introduction of biosimilars [2][16] Pipeline and Future Catalysts - The company estimates combined peak sales of over $43 billion across 20 development-stage therapies, translating to more than $2.1 billion in peak annual royalties [11] - Upcoming pivotal readouts are expected over the next 24 months, including data from Revolution Medicines and Novartis [17] Capital Allocation - Royalty Pharma returned $1.7 billion to shareholders in 2025 through $1.2 billion in buybacks and over $500 million in dividends [14]

Core Insights - Royalty Pharma (RPRX) is expected to report quarterly earnings of $1.33 per share, reflecting a 15.7% increase year-over-year, with revenues projected at $824.89 million, an 11.2% increase from the previous year [1] Earnings Projections - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating stability in expectations [1] - The importance of earnings estimate revisions is highlighted as they are a critical gauge for predicting investor behavior [2] Key Metrics Projections - Analysts predict 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' will reach $230.74 million, a decrease of 2.6% year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is expected to reach $64.04 million, reflecting a 5% increase from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is projected at $41.09 million, indicating a 10.7% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is expected to reach $49.32 million, a 7.2% increase from the previous year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is projected at $22.16 million, showing a significant decrease of 49.6% year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is expected to reach $57.64 million, reflecting a 47.8% increase [6] - 'Portfolio Receipts- Milestones and other contractual receipts' is estimated at $11.40 million, a decrease of 12.4% year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is projected at $58.82 million, indicating a 5% increase [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is expected to reach $11.79 million, a 7.1% increase from the previous year [8] - The total for 'Portfolio Receipts- Royalty Receipts- Products' is projected at $813.50 million, reflecting an 11.6% increase year-over-year [8] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $93.70 million, indicating a 26.6% increase [9] - 'Portfolio Receipts- Royalty Receipts- Products- Spinraza' is projected at $13.37 million, suggesting a 10.9% decrease year-over-year [9] Stock Performance - Over the past month, shares of Royalty Pharma have returned +9.4%, while the Zacks S&P 500 composite has shown no change [9]

Core Insights - Novartis reported high single-digit sales growth for 2025, achieving a 40.1% core margin two years ahead of schedule, with full-year sales rising 8% and core operating income increasing 14% to CHF 21.9 billion [3][4][6] Financial Performance - In Q4, sales declined by 1%, while core operating income rose by 1%. Excluding R&D-related adjustments, underlying Q4 sales growth would have been approximately 3% [2][6] - For the full year, core EPS increased by 17% to $8.98, and free cash flow grew by 8% to CHF 17.6 billion, marking an all-time high for the company [3][6] Product and Pipeline Momentum - Priority brands such as Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix, and Cosentyx showed strong growth, with Kisqali sales rising 57% to CHF 4.8 billion and Kesimpta sales increasing 36% to $4.4 billion [5][7][15] - Pluvicto achieved $2 billion in global sales with a 42% constant-currency growth, while Leqvio reached blockbuster status with 57% full-year growth [7][15] Pipeline Updates - Novartis highlighted several pipeline developments, including a submission for remibrutinib and updates on the renal portfolio, with a revised timeline for the zigakibart phase III protocol expected in the first half of 2027 [8][9] - Data from the Phase III MANIFEST program for pelabresib provided a path forward for registration, with plans for a new Phase III study targeting patients with high baseline symptom burden [10] 2026 Outlook - The company anticipates low single-digit sales growth for 2026, with a core margin decline of one to two percentage points due to the Avidity deal, describing the year as "a year of two halves" [12][14] - The first half of 2026 is expected to see low single-digit sales decline and low double-digit core operating income decline, while the second half is projected to grow mid-single-digit in sales and mid- to high single-digit in core operating income [14] Capital Allocation - In 2025, Novartis invested over $10 billion in R&D, completed a CHF 15 billion buyback program, and proposed a dividend of CHF 3.70 per share, marking the 29th consecutive dividend increase [16]

Core Insights - Novartis AG reported fourth-quarter 2025 net sales of $13.34 billion, a 1% year-over-year increase, but below Wall Street's estimate of $13.78 billion [1] - On a constant-currency basis, sales decreased by 1% [1] - The company faced a significant negative impact from generic competition, which reduced sales by 15 percentage points, including a 3 percentage point impact from revenue deduction adjustments in the U.S. related to Entresto and Promacta [1] Financial Performance - Pricing pressures negatively impacted sales by 4 percentage points, while currency fluctuations had a positive impact of 2 percentage points [2] - Core operating income increased by 1% to $4.93 billion, with a core operating income margin of 37.0%, reflecting a slight increase of 0.1 percentage points [2] - The growth in core operating income was supported by higher government grant income and lower selling, general, and administrative (SG&A) expenses, although this was partially offset by increased research and development (R&D) expenses [2] Product Performance - Strong demand for key therapies contributed to growth, with Kisqali sales rising 44% to $1.32 billion, Kesimpta increasing 27% to $1.23 billion, and Cosentyx revenue up 11% to $1.81 billion [3] - Scemblix saw an 87% increase to $391 million, while Pluvicto advanced 70% to $605 million [3] Future Outlook - For fiscal 2026, Novartis anticipates low single-digit growth in net sales, while core operating income is expected to decrease in the low single digits [5] - The incoming CFO indicated that adjusted operating income is projected to grow significantly in the second half of 2026, which is expected to positively impact 2027 and beyond [5] - Novartis shares rose 1.79% to $152.54, reaching a new 52-week high [5]

Summary of Novartis Conference Call Company Overview - **Company**: Novartis - **Event**: 44th J.P. Morgan Healthcare Conference - **CEO**: Vasant Narasimhan Key Points Financial Performance - Novartis achieved a **7%** increase in sales and a **15%** increase in core operating income over recent years [2] - The core operating margin is projected to reach **38.7%** by 2024, with a target of **40%** [2][3] - Free cash flow generation was **$16 billion** last year and is on track for the same in 2025 [3] - Return on invested capital has improved to **17%**, positioning Novartis in the top quartile among peers [3] Strategic Focus - The company has transitioned to a pure-play medicines company, focusing on high-end technologies in four core therapeutic areas [2][4] - Capital allocation priorities include organic business investment, value-creating bolt-ons, and ongoing share buybacks, with a **$15 billion** share buyback program initiated [5] - Novartis aims to consistently grow dividends in Swiss francs [5] Pipeline and Growth Opportunities - Novartis has **14 in-market blockbusters** and **nine brands** with multi-billion-dollar peak sales potential [6] - The company is entering a catalyst-rich period with **15 submission-enabling readouts** expected in the next two years [6][14] - Significant market opportunities identified in RNA therapeutics (**$36 billion**), radioligand therapies (**$28 billion**), and cell and gene therapies (up to **$50 billion**) [7] Long-term Guidance - Novartis projects **high single-digit growth** for 2024-2025, **5%-6% growth** through 2030, and **mid-single-digit growth** beyond 2030 [8] - The company aims to grow revenues to **$60 billion** to **$80 billion** by the middle of the next decade [9] Commercial Execution - Strong commercial execution noted in the U.S. and international markets, with significant market shares achieved for products like Cosentyx and Kisqali [11][12] - Novartis is ranked **number two in China**, **number one in Germany**, and **number four in Japan** [12] Product Launches and Approvals - Kisqali is projected to exceed **$10 billion** in peak sales, while Scemblix is expected to reach over **$4 billion** [13] - The launch of Roxido is a top priority, with expectations for it to become a multi-billion-dollar medicine [13] - Remibrutinib is highlighted as a key asset with potential in multiple indications, including food allergies and hidradenitis [21] Oncology and R&D Strategy - Novartis is focusing on expanding its oncology pipeline, with a strong emphasis on radioligand therapies and small molecules [27][46] - The company has appointed a new oncology R&D chief to strengthen its leadership in this area [50] ESG and Global Health Initiatives - Novartis emphasizes its commitment to ESG and global health, with notable achievements in malaria treatment [30] Market Challenges and Considerations - The company anticipates **1%-2% margin dilution** from the acquisition of Avidity and the impact of recent healthcare reforms [10][66] - Guidance includes considerations for potential pricing impacts from the Inflation Reduction Act [66] Conclusion - Novartis is positioned for continued growth with a robust pipeline, strong financial performance, and a commitment to shareholder value through strategic investments and acquisitions [31]

Financial Data and Key Metrics Changes - The company reported an 11% growth in both portfolio receipts and royalty receipts, indicating strong business momentum [4][22] - Return on invested capital was 15.7% and return on invested equity was 22.9% for the last 12 months [6][25] - Portfolio receipts for Q3 2025 reached $814 million, reflecting an 11% increase [22] Business Line Data and Key Metrics Changes - The company maintained strong growth driven by key products such as Voranigo, Tremfya, and the Cystic Fibrosis Franchise [22] - The development stage pipeline expanded to 17 therapies, with multiple pivotal readouts expected in the near future [7][15] Market Data and Key Metrics Changes - The company raised its full-year 2025 top line guidance to between $3.2 billion and $3.25 billion, representing growth of approximately 14-16% [9][20] - Milestones and other contractual receipts are now expected to be around $125 million, up from $110 million previously [20] Company Strategy and Development Direction - The company aims to be the premier capital allocator in life sciences, focusing on innovative therapies with high patient impact [4][31] - The strategy includes a therapy area agnostic investment approach, allowing for diversification across various disease areas [10][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for funding life sciences innovation, highlighting the potential for annualized total shareholder returns in the mid-teens over the next five years [31] - The company is excited about growth opportunities in China, particularly in out-licensing to multinationals [39] Other Important Information - The company deployed $1 billion in capital for value-creating royalty transactions in Q3 2025, totaling $1.7 billion for the first nine months [6][26] - Share repurchases amounted to $1.15 billion in the first nine months of 2025 [26] Q&A Session Summary Question: Impact of biotech M&A and interest rates on royalty-driven deal activity - Management noted that the uptick in M&A activity does not significantly impact their operations, as large pharma companies require capital, which the company provides [38] Question: Thoughts on the China opportunity - Management is optimistic about growth in China and is actively building relationships to capitalize on this market [39] Question: Frequency of collaborations with large pharma - Management believes the use of royalties to fund trials is becoming mainstream, indicating a growing opportunity in this area [41] Question: Insights on the Amvuttra deal and competition - Management expressed confidence in the Amvuttra investment despite potential competition from Nucresiran, citing a broad range of scenarios considered [60] Question: Updates on the LP(a) space and trial designs - Management acknowledged differences in trial designs and remains optimistic about the prospects of their investments in this area [90] Question: Updates on obexelimab and its market potential - Management highlighted the strong phase 2 data for obexelimab, validating its potential in treating autoimmune diseases [92]